Latest Conference Articles

Can We Provide Tailored Care for Homeless HIV Patients?

Can We Provide Tailored Care for Homeless HIV Patients?

July 23rd 2021, 5:00pm

IAS Conference

A discussion as to why people with unstable housing living with HIV may not prefer telehealth versus consistent in-person care.

Shifting COVID-19 Concerns in the HIV Community

Shifting COVID-19 Concerns in the HIV Community

July 23rd 2021, 1:00pm

IAS Conference

The risk of COVID-19 severity in people living with HIV may be less than previously anticipated.

Once-Monthly PrEP May Become a Viable HIV Option

Once-Monthly PrEP May Become a Viable HIV Option

July 23rd 2021, 11:00am

IAS Conference

Phase 3 trials for islatravir are underway. What are investigators considering with the Merck investigative drug?

Increasing Family Physician Engagement with PrEP Therapy

Increasing Family Physician Engagement with PrEP Therapy

July 22nd 2021, 7:26pm

IAS Conference

Due to limited familiarity with providing antiretroviral medication, many participants were hesitant to initiate PrEP.

Evaluating Adherence of PrEP Therapies

Evaluating Adherence of PrEP Therapies

July 22nd 2021, 1:00pm

IAS Conference

Investigators wanted to study usage of F/TAF vs F/TDF in clinical practice and HIV seroconversion.

How Does Adherence of Daily Dosing vs Event-Driven PrEP Regimens Compare?

How Does Adherence of Daily Dosing vs Event-Driven PrEP Regimens Compare?

July 21st 2021, 7:00pm

IAS Conference

Adherence for daily dosing decreased and event-driven PrEP usage increased in a Chinese study.

Resilience in People Living With HIV During the COVID-19 Pandemic

Resilience in People Living With HIV During the COVID-19 Pandemic

July 21st 2021, 4:47pm

IAS Conference

Impaired resilience was found to be associated with loneliness.

Providing Online HIV Services During the COVID-19 Pandemic

Providing Online HIV Services During the COVID-19 Pandemic

July 21st 2021, 3:10pm

IAS Conference

Virtual support services were crucial for providing continued care and education.

Screening for Potential PrEP Users at Retail Pharmacies

Screening for Potential PrEP Users at Retail Pharmacies

July 21st 2021, 1:00pm

IAS Conference

In a pilot project, customers were surveyed about HIV risk behaviors to gain further insights and assessed for potential PrEP utilization.

Islatravir Safe, Tolerable for HIV-1 PrEP in Phase 2A Trial

Islatravir Safe, Tolerable for HIV-1 PrEP in Phase 2A Trial

July 20th 2021, 9:31pm

IAS Conference

New 24-week findings from Merck highlight the potential of a 1-month PrEP option for low-risk patients.